Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Patient specific circulating tumor DNA fingerprints to monitor treatment response across multiple tumors.

Journal of translational medicine - 1 Aug 2020

Li Jiaping, Jiang Wei, Wei Jinwang, Zhang Jianwei, Cai Linbo, Luo Minjie, Wang Zhan, Sun Wending, Wang Shengzhou, Wang Chen, Dai Chun, Liu Jun, Wang Guan, Wang Jiping, Xu Qiang, Deng Yanhong

Abstract excerpt

BACKGROUND: Circulating tumor DNA (ctDNA) offers a convenient way to monitor tumor progression and treatment response. Because tumor mutational profiles are highly variable from person to person, a fixed content panel may be insufficient to track treatment response in all patients. METHODS: We design ctDNA fingerprint panels specific to individual patients which are based on whole exome sequencing and target to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Neoplasm

Share to Genes, Neoplasm

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 32738923
DOI: 10.1186/s12967-020-02449-y
PMCID: PMC7395971

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Patient specific circulating tumor DNA fingerprints to monitor treatment response across multiple tumors.PMID 32738923Read ↗

Individualized ctDNA Fingerprints to Monitor Treatment Response and Recurrence in Multiple Cancer TypesSemantic proximity Read ↗

Noninvasive MRD monitoring and profiling of clonal evolution by ctDNA in patients with advanced cancers treated within molecular tumor boardsSemantic proximity Read ↗

Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncologySemantic proximity Read ↗

Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study.Semantic proximity Read ↗

Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors.Semantic proximity Read ↗

Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer Types.Semantic proximity Read ↗

Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.Semantic proximity Read ↗

Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: Current research, opportunities, and challengesSemantic proximity Read ↗

Concurrent Tissue and Circulating Tumor DNA Molecular Profiling to Detect Guideline-Based Targeted Mutations in a Multicancer Cohort.Semantic proximity Read ↗

A Pilot Study Analyzing the Clinical Utility of Comprehensive Genomic Profiling Using Plasma Cell-Free DNA for Solid Tumor Patients in Japan (PROFILE Study).Semantic proximity Read ↗

Personalized medicine using DNA biomarkers: a reviewSemantic proximity Read ↗

Therapeutic Monitoring of Circulating DNA Mutations in Metastatic Cancer with Personalized Digital PCR.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.